[go: up one dir, main page]

PE20140750A1 - Tratamiento del mieloma multiple - Google Patents

Tratamiento del mieloma multiple

Info

Publication number
PE20140750A1
PE20140750A1 PE2013002426A PE2013002426A PE20140750A1 PE 20140750 A1 PE20140750 A1 PE 20140750A1 PE 2013002426 A PE2013002426 A PE 2013002426A PE 2013002426 A PE2013002426 A PE 2013002426A PE 20140750 A1 PE20140750 A1 PE 20140750A1
Authority
PE
Peru
Prior art keywords
multiple myeloma
subject
myeloma cells
prevalence
administer
Prior art date
Application number
PE2013002426A
Other languages
English (en)
Inventor
Christopher John Burns
Andrew Spencer
Katherine Anne Monaghan
Original Assignee
Ym Biosciences Australia Pty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47107683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140750(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ym Biosciences Australia Pty filed Critical Ym Biosciences Australia Pty
Publication of PE20140750A1 publication Critical patent/PE20140750A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UN METODO PARA TRATAR UN SUJETO QUE PRESENTA MIELOMA MULTIPLE EN UN ESTADIO CARACTERIZADO POR UN AUMENTO EN LA PREVALENCIA DE CELULAS DE MIELOMA MULTIPLE QUE SON NO RESPONDEDORAS A IL-6 O TIENEN UN FENOTIPO CD45-, EN DONDE EL METODO COMPRENDE: A) SELECCIONAR UN SUJETO DIAGNOSTICADO CON UN AUMENTO EN LA PREVALENCIA DE CELULAS DE MIELOMA MULTIPLE; B) ADMINISTRAR AL SUJETO UNA CANTIDAD DEL COMPUESTO CYT387 QUE ES N-(CIANOMETIL)-4-[2-[[4-(4-MORFOLINIL)FENIL]AMINO]-4-PIRIMIDINIL]-BENZAMIDA EFICAZ PARA REDUCIR LA VIABILIDAD DE DICHAS CELULAS DE MIELOMA MULTIPLE; Y C) ADMINISTRAR UN SEGUNDO AGENTE TERAPEUTICO TAL COMO MELFALAN Y BORTEZOMIB
PE2013002426A 2011-05-02 2012-05-01 Tratamiento del mieloma multiple PE20140750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161481425P 2011-05-02 2011-05-02

Publications (1)

Publication Number Publication Date
PE20140750A1 true PE20140750A1 (es) 2014-07-06

Family

ID=47107683

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002426A PE20140750A1 (es) 2011-05-02 2012-05-01 Tratamiento del mieloma multiple

Country Status (21)

Country Link
US (1) US20140171433A1 (es)
EP (1) EP2704722A4 (es)
JP (1) JP2014514337A (es)
KR (1) KR20140081757A (es)
CN (1) CN103533939A (es)
AP (1) AP2013007281A0 (es)
AU (1) AU2012250491A1 (es)
BR (1) BR112013028420A2 (es)
CA (1) CA2834414A1 (es)
CL (1) CL2013003143A1 (es)
CO (1) CO6900134A2 (es)
EA (1) EA201391591A1 (es)
IL (1) IL228981A0 (es)
MA (1) MA35129B1 (es)
MD (1) MD20130089A2 (es)
MX (1) MX2013012785A (es)
PE (1) PE20140750A1 (es)
PH (1) PH12013502144A1 (es)
SG (1) SG194212A1 (es)
WO (1) WO2012149602A1 (es)
ZA (1) ZA201308918B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
EP3148545B1 (en) 2014-05-28 2023-03-15 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
TW202134236A (zh) * 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
EP3171892B1 (en) 2014-07-22 2021-11-24 Apollomics Inc. Anti-pd-1 antibodies
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN105837515B (zh) * 2016-04-06 2018-08-03 中国药科大学 一种JAK抑制剂Momelotinib的制备方法
CN106075046A (zh) * 2016-07-31 2016-11-09 孙书芳 一种治疗肝肾阴虚型多发性骨髓瘤的中药
US10487321B2 (en) * 2016-09-29 2019-11-26 PZM Diagnostics, LLC Method of extraction of genomic DNA for molecular diagnostics and application
WO2019055930A1 (en) * 2017-09-15 2019-03-21 University Of Iowa Research Foundation METHODS OF IDENTIFYING MYELOMA TUMOR INITIATOR CELLS AND TARGETED THERAPY
CN109045040A (zh) * 2018-03-12 2018-12-21 首都医科大学附属北京天坛医院 Cyt387用于制备治疗神经胶质瘤的药物的应用
CN111100076A (zh) * 2019-12-30 2020-05-05 武汉九州钰民医药科技有限公司 Jak抑制剂莫美洛替尼的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750697A4 (en) * 2004-05-05 2009-08-26 Celgene Corp METHODS AND COMPOSITIONS USING CYTOKINE INHIBITION DRUGS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
JP2010510971A (ja) * 2006-11-27 2010-04-08 アレス トレーディング ソシエテ アノニム 多発性骨髄腫の治療
KR101737753B1 (ko) * 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도

Also Published As

Publication number Publication date
CL2013003143A1 (es) 2014-07-04
EA201391591A1 (ru) 2014-12-30
SG194212A1 (en) 2013-11-29
WO2012149602A1 (en) 2012-11-08
MD20130089A2 (ro) 2014-05-31
EP2704722A4 (en) 2014-11-05
KR20140081757A (ko) 2014-07-01
PH12013502144A1 (en) 2017-10-25
MA35129B1 (fr) 2014-05-02
AP2013007281A0 (en) 2013-11-30
IL228981A0 (en) 2013-12-31
US20140171433A1 (en) 2014-06-19
MX2013012785A (es) 2014-05-28
JP2014514337A (ja) 2014-06-19
AU2012250491A1 (en) 2013-05-02
CA2834414A1 (en) 2012-11-08
ZA201308918B (en) 2014-08-27
CO6900134A2 (es) 2014-03-20
BR112013028420A2 (pt) 2017-01-24
EP2704722A1 (en) 2014-03-12
CN103533939A (zh) 2014-01-22

Similar Documents

Publication Publication Date Title
PE20140750A1 (es) Tratamiento del mieloma multiple
BR112012023021A2 (pt) compostos de indazol e seus usos
EA201491008A1 (ru) Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
BR112015022197A2 (pt) tratamento de cataplexia
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
MX375417B (es) Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado.
MX384721B (es) Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MX2014008021A (es) Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
MX385122B (es) Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica.
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
PH12013502677A1 (en) Benzylamine derivatives as inhibitors of plasma kallikrein
MX2015008187A (es) Inhibidores de alk deuterados.
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
IN2015DN04311A (es)
MX343931B (es) Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical.
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
PE20150709A1 (es) Benzamidas
MX2014000781A (es) Dosis combinada fija de bimatoprost y brimonidina.
EA201491500A1 (ru) Способы лечения фиброза
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
GT201400306A (es) Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
MX2014005749A (es) Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp).

Legal Events

Date Code Title Description
FD Application declared void or lapsed